drugset / Trial / NCT03216187
Swiss Multi-centre, Randomized, Placebo Controlled Trial of Pregabalin for Prevention of Persistent Pain in High Risk Patients Undergoing Breast Cancer Surgery
Phase 3
Terminated
126 enrolled
Benno Rehberg-Klug
Centre Hospitalier Universitaire Vaudois · collabInsel Gruppe AG, University Hospital Bern · collabUniversity Hospital, Geneva · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This study will test the benefits and risks of using pregabalin perioperatively to prevent persistent postoperative pain in patients at high risk (\>30%) of developing such pain after breast cancer surgery.
Timeline
- Start
- 2018-01-09
- Primary completion
- 2024-06-11
- Completion
- 2024-11-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pregabalin | Small molecule | 150 mg | — |
Indications
No indication recorded.